Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions

被引：7

作者：

Chibaudel, Benoist ^{[1
,2
]}

Tournigand, Christophe ^{[1
]}

Andre, Thierry ^{[3
]}

Larsen, Annette K. ^{[4
]}

de Gramont, Aimery ^{[1
,4
]}

机构：

[1] Hop St Antoine, AP HP, Med Oncol Serv, F-75012 Paris, France

[2] Grp Cooperateur Multidisciplinaire Oncol, GERCOR, Paris, France

[3] Hop La Pitie Salpetriere, AP HP, Paris, France

[4] Inst Natl Sante & Rech Med, UMR S 893, Paris, France

来源：

CLINICAL COLORECTAL CANCER | 2010年 / 9卷 / 05期

关键词：

Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; KRAS; XelOx; III COLON-CANCER; RANDOMIZED PHASE-III; LOW-DOSE LEUCOVORIN; 1ST-LINE TREATMENT; PLUS FLUOROURACIL; BOLUS FLUOROURACIL; TREATMENT TX; OXALIPLATIN; TRIAL; BEVACIZUMAB;

D O I：

10.3816/CCC.2010.n.039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be better than chemotherapy alone, even in selected wild-type KRAS populations. A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials.

引用

页码：269 / 273

页数：5

共 45 条

[1] Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Colangelo, Linda H. ;

Lopa, Samia H. ;

Petrelli, Nicholas J. ;

Goldberg, Richard M. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390

[2] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[3] Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial [J].

André, T ;

Colin, P ;

Louvet, C ;

Gamelin, E ;

Bouche, O ;

Achille, E ;

Colbert, N ;

Boaziz, C ;

Piedbois, P ;

Tubiana-Mathieu, N ;

Boutan-Laroze, A ;

Flesch, M ;

Buyse, M ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2896-2903

[4] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].

Andre, Thierry ;

Boni, Corrado ;

Navarro, Matilde ;

Tabernero, Josep ;

Hickish, Tamas ;

Topham, Clare ;

Bonetti, Andrea ;

Clingan, Philip ;

Bridgewater, John ;

Rivera, Fernando ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116

[5]

[Anonymous], J CLIN ONCOL S

[6]

[Anonymous], AJCC CANC STAG MAN

[7]

[Anonymous], 2009, CANC FACTS FIG 2009

[8] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[9] Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center trial TRC-0301 [J].

Chen, Helen X. ;

Mooney, Margaret ;

Boron, Matthew ;

Vena, Don ;

Mosby, Kimberly ;

Grochow, Louise ;

Jaffe, Carl ;

Rubinstein, Lawrence ;

Zwiebel, James ;

Kaplan, Richard S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3354-3360

[10] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

← 1 2 3 4 5 →